Sosei Heptares bags another big partnership, this time with TakedaJapanese biotech Sosei’s buyout of the UK’s Heptares four years ago has rewarded it with a string of Share XSosei Heptares bags another big partnership, this time with Takedahttps://pharmaphorum.com/news/sosei-heptares-bags-another-big-partnership-this-time-with-takeda/
Takeda looking to divest portfolio of older drugs in EuropeTakeda is trying to sell a portfolio of older drugs in western Europe as it seeks to cut Share XTakeda looking to divest portfolio of older drugs in Europehttps://pharmaphorum.com/news/takeda-looking-to-divest-portfolio-of-older-drugs-in-europe/
Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialCatalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market Share XCatalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialhttps://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/
Takeda’s Ninlaro fails phase 3 amyloidosis trialTakeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not Share XTakeda’s Ninlaro fails phase 3 amyloidosis trialhttps://pharmaphorum.com/news/takedas-ninlaro-fails-phase-3-amyloidosis-trial/
Takeda to sell dry eye drug to Novartis for up to $5.3bnTakeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch Share XTakeda to sell dry eye drug to Novartis for up to $5.3bnhttps://pharmaphorum.com/news/takeda-to-sell-dry-eye-drug-to-novartis-for-up-to-5-3bn/
NICE backs interim funding for J&J/Takeda myeloma regimenA three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be Share XNICE backs interim funding for J&J/Takeda myeloma regimenhttps://pharmaphorum.com/news/nice-backs-interim-funding-for-jj-takeda-myeloma-regimen/
Takeda’s Entyvio outperforms AbbVie’s Humira in GI trialTakeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – Share XTakeda’s Entyvio outperforms AbbVie’s Humira in GI trialhttps://pharmaphorum.com/news/takedas-entyvio-outperforms-abbvies-humira-in-gi-trial/
Takeda mulling sale of emerging market drugs – reportTakeda could be considering selling some emerging-market drugs in a bid to cut debts following its merger with Share XTakeda mulling sale of emerging market drugs – reporthttps://pharmaphorum.com/news/takeda-could-sell-emerging-market-drugs/
Takeda’s Shire takeover could herald new era of pharma M&ATakeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in Share XTakeda’s Shire takeover could herald new era of pharma M&Ahttps://pharmaphorum.com/news/takedas-shire-takeover-could-herald-new-era-of-pharma-ma/
